VANCOUVER, BC, March 30, 2026 /PRNewswire/ – NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F) (“Other” or that “Company”), is currently reporting financial results for the 2025 fiscal year ending December 31, 2025. The financial statements and MD&A are available on SEDAR under the Company profile.
“2025 is a transformational year for Else Nutrition,” commented Hamutal Yitzhak, Chief Executive Officer and Co-Founder of Else Nutrition. “Although we face significant challenges, including funding constraints for production and operations and prolonged out-of-stock periods, we are making significant progress in increasing efficiency, reducing costs, and strengthening our financial position – laying the foundation for continued growth in 2026 and beyond.
“We implemented several key operational changes. In Canada, we moved from a distribution model to a direct retail model and, in Q1 2026, continued sales in the main retail channels. In the US, we replaced B2B and B2C third-party logistics providers with a smooth implementation.
“Furthermore, sales and marketing expenses were reduced by more than 60%. Despite this significant reduction, US revenue decreased by 18.5%, primarily driven by an extended out-of-stock period for our ready-to-drink cereal and children’s products. (COGS) decreased by 38%, including approximately CAD $750,000 in write-offs related primarily to older raw materials and Canadian products. Excluding these one-time items, COGS would have decreased by 46%-almost double the rate of decline in income Importantly, we achieved a return to positive gross profit in 2025,000,000,000,000, compared to 2025. 2024, reflecting the impact of cost optimization and operational efficiency initiatives.
“We have seen the impact of this initiative. We have continued to deliver to Canadian retailers at significantly higher margins, we are gradually closing inventory gaps, and seeing revenue begin to recover – especially online. As a result, we are more confident in our ability to achieve profitability in the next 12 months.”
“At the same time, we continue to advance our plant-based infant formula program, which represents the most significant long-term growth opportunity. Importantly, the US regulatory environment has begun to shift in a meaningful way. In November 2025, the US federal budget was signed into law including a Congressional directive for the Food & Drug Administration to establish a clearer and more efficient approval path for a broader non-dairy portion of plant-based non-dairy businesses. Operation Stork Speed This Directive is expected accelerate regulatory guidance and create a clearer path to market innovative formula solutions like ours.
“More recently, in March 2026, the US Food and Drug Administration officially announced its intention to finalize the Protein Efficiency Ratio (PER) guidelines. Actively developing dedicated guidance to manage PER study design, evaluation criteria, and important methodological expectations, this development represents a significant achievement for Else, as the PER requirement has long been a key blocker preventing the continuation of clinical studies. PER. reformation of the regulation of infant formula”.
“We believe this development represents a critical inflection point for the category, because it signals increased regulatory support for innovation and expands the opportunity to bring inclusive, plant-based nutritional options for families looking for alternatives to traditional milk- and soy-based formulas. With this momentum, we are in active discussions with the FDA and preparing for the next phase of clinical and commercial development, other positioning has been implemented in the US market more efficiently.
“Looking ahead, we remain focused on executing against our key priorities, including further optimizing our cost structure, advancing manufacturing efficiency, expanding our commercial footprint, and progressing regulatory milestones. With a strong foundation in place, we believe we are on track to achieving cash-flow breakeven between late 2026 and delivering long-term value in 2027.” Yitzchak.
2025 Financial Results
All figures are in CAD unless otherwise stated.
- Revenue was approximately $6.0 million for fiscal year 2025 compared to $8.0 million for fiscal year 2024.
- Operating expenses are $6.7 million for fiscal year 2025 compared to $13.6 million for fiscal year 2024.
- Gross profit of $320 thousand dollars for fiscal year 2025 compared to gross loss of $1.2 million dollars for fiscal year 2024.
- Cash balance as of December 31, 2025, is $171 thousand dollars, including restricted cash.
Information about the company Else Nutrition Holdings Inc.
Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: 0YL) is an international expansion-stage food and nutrition company focused on developing innovative, clean, plant-based food and nutrition products for infants, toddlers, children, and adults. The revolutionary, plant-based, non-soy formula is a clean ingredient alternative to milk-based formulas. Since launching Plant-Based Complete Nutrition for Kids, made with whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of testimonials and strong reviews from parents, gained the support of national retailers, and achieved rapid sales growth.
Awards and Recognition:
- “2017 Best Health and Diet Solutions” award at the Milan Global Food Innovation Summit
- #1 Best Seller on Amazon in Fall 2020 in the New Baby & Toddler Formula Category
- “Best Milk Alternative” Award 2021 at the World Plant-Based Expo
- Nexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle category
- As of September 2022, Other Super Cereal achieved #1 Best Seller in Baby Cereal across all brands on Amazon.
- In May 2024 Élse Nutrition’s Ready-to-Innum Kids Vanilla Shake Named Among the Best in Family-Friendly Products by the Prestigious Mom’s Choice Awards®
TSX
Neither the TSX nor its regulatory service providers (as those terms are defined in TSX policies) accept responsibility for the adequacy or accuracy of this release.
Caution About Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are usually identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements regarding the anticipated date for filing the company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs, and assumptions, which are based on management’s perception of current conditions and future developments, as well as factors that management believes are appropriate under the circumstances. No guarantee can be given that the above will prove to be correct. Forward-looking statements made in this press release assume, among other things, the expectation that there will be no supply chain disruptions or failures as a result of COVID-19 and that manufacturing, brokerage, and supply logistics agreements with the company are not terminated. Actual results may differ from estimates, beliefs, and assumptions expressed or implied in forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
SOURCE Else Nutrition Holdings Inc.
#Nutrition #Reports #Fiscal #Year #Financial #Results #Highlights #Operational #Progress #Strengthened #Financial #Foundations #Clear #Path #Profitability